Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus PT from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $23.00.

AURA has been the subject of several research reports. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 23,045 shares of company stock worth $177,242 over the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

A number of large investors have recently made changes to their positions in AURA. Barclays PLC lifted its holdings in Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares during the last quarter. State Street Corp lifted its holdings in Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after acquiring an additional 26,841 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after acquiring an additional 39,379 shares during the last quarter. Wellington Management Group LLP acquired a new position in Aura Biosciences in the third quarter valued at approximately $1,037,000. Finally, Franklin Resources Inc. lifted its holdings in Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after acquiring an additional 215,597 shares during the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Trading Up 3.0 %

NASDAQ:AURA opened at $7.50 on Thursday. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $8.72. The firm has a market cap of $374.63 million, a P/E ratio of -4.34 and a beta of 0.29.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.